OTCMKTS:POLXFPolydex Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Polydex Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.99 0.00 (0.00 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$0.99Now: $0.99▼$0.9950-Day Range$0.80MA: $0.97▼$1.0552-Week Range$0.80Now: $0.99▼$1.29VolumeN/AAverage Volume2,633 shsMarket Capitalization$3.39 millionP/E Ratio14.14Dividend YieldN/ABeta0.38 ProfileAdvanced ChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Polydex Pharmaceuticals. Previous Next 2.6 Community Rank Outperform VotesPolydex Pharmaceuticals has received 84 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPolydex Pharmaceuticals has received 76 “underperform” votes. (Add your “underperform” vote.)Community SentimentPolydex Pharmaceuticals has received 52.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Polydex Pharmaceuticals and other stocks. Vote “Outperform” if you believe POLXF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe POLXF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPolydex Pharmaceuticals does not currently pay a dividend.Dividend GrowthPolydex Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Polydex Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.90% of the stock of Polydex Pharmaceuticals is held by insiders. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Polydex Pharmaceuticals is 14.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Polydex Pharmaceuticals is 14.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 19.91.Price to Book Value per Share RatioPolydex Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.77 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Industrial inorganic chemicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:POLXF Previous Symbol CUSIPN/A CIK317158 Webwww.polydex.com Phone416-755-2231Debt Debt-to-Equity Ratio0.03 Current Ratio4.05 Quick Ratio2.70Price-To-Earnings Trailing P/E Ratio14.14 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.14 million Price / Sales0.66 Cash Flow$0.15 per share Price / Cash Flow6.61 Book Value$1.69 per share Price / Book0.59Profitability EPS (Most Recent Fiscal Year)N/A Net Income$250,000.00 Net Margins4.88% Return on Equity4.22% Return on Assets3.36%Miscellaneous Employees23 Outstanding Shares3,420,000Market Cap$3.39 million Next Earnings Date6/15/2020 (Estimated) OptionableNot Optionable OTC:POLXF Rates by TradingView Receive POLXF News and Ratings via Email Sign-up to receive the latest news and ratings for POLXF and its competitors with MarketBeat's FREE daily newsletter. Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions How has Polydex Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Polydex Pharmaceuticals' stock was trading at $1.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, POLXF shares have decreased by 6.6% and is now trading at $0.99. View which stocks have been most impacted by Coronavirus. When is Polydex Pharmaceuticals' next earnings date? Polydex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, June 15th 2020. View our earnings forecast for Polydex Pharmaceuticals. How were Polydex Pharmaceuticals' earnings last quarter? Polydex Pharmaceuticals Ltd (OTCMKTS:POLXF) issued its quarterly earnings data on Thursday, April, 30th. The company reported ($0.04) EPS for the quarter. The company earned $1.46 million during the quarter. Polydex Pharmaceuticals had a net margin of 4.88% and a return on equity of 4.22%. View Polydex Pharmaceuticals' earnings history. Has Polydex Pharmaceuticals been receiving favorable news coverage? Media stories about POLXF stock have trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Polydex Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPolydex Pharmaceuticals. Who are some of Polydex Pharmaceuticals' key competitors? Some companies that are related to Polydex Pharmaceuticals include Linde (LIN), Air Products & Chemicals (APD), JSR CORP/ADR (JSCPY), Minerals Technologies (MTX), Kronos Worldwide (KRO), Tronox (TROX), Luxfer (LXFR), Valhi (VHI), Venator Materials (VNTR), NL Industries (NL), LSB Industries (LXU) and TOR Minerals International (TORM). View all competitors. Who are Polydex Pharmaceuticals' key executives? Polydex Pharmaceuticals' management team includes the following people: Mr. George G. Usher, Chairman, CEO & Pres (Age 60)Ms. Sharon L. Wardlaw, COO, Treasurer & Sec. (Age 66)Mr. David Jamestee, Chief Financial Officer What is Polydex Pharmaceuticals' stock symbol? Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF." How do I buy shares of Polydex Pharmaceuticals? Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Polydex Pharmaceuticals' stock price today? One share of POLXF stock can currently be purchased for approximately $0.99. How big of a company is Polydex Pharmaceuticals? Polydex Pharmaceuticals has a market capitalization of $3.39 million and generates $5.14 million in revenue each year. Polydex Pharmaceuticals employs 23 workers across the globe. What is Polydex Pharmaceuticals' official website? The official website for Polydex Pharmaceuticals is www.polydex.com. How can I contact Polydex Pharmaceuticals? Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
